Processa Pharmaceuticals ( (PCSA) ) has issued an announcement.
On January 27, 2025, Processa Pharmaceuticals entered into a securities purchase agreement with a healthcare-focused institutional investor, resulting in the sale of shares and warrants in a public offering. The offering closed on January 29, 2025, raising approximately $5 million in gross proceeds, which the company intends to use for general corporate purposes, marking a significant financial move within the industry.
More about Processa Pharmaceuticals
Processa Pharmaceuticals is a clinical-stage pharmaceutical company focusing on developing Next Generation Chemotherapy (NGC) drugs designed to enhance safety and efficacy. These drugs are modifications of existing FDA-approved oncology therapies that alter metabolism or distribution while maintaining cancer-killing mechanisms.
YTD Price Performance: -34.22%
Average Trading Volume: 393,831
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.18M
For detailed information about PCSA stock, go to TipRanks’ Stock Analysis page.